Malaria No More and Novartis launch Power of One, a global digital fundraising campaign to help eliminate malaria deaths
(Thomson Reuters ONE) -
Novartis International AG /
Malaria No More and Novartis launch Power of One, a global digital fundraising
campaign to help eliminate malaria deaths
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Power of One enables the public to fund malaria tests and treatments for
children in Africa through the latest online and mobile technology
* Novartis is the exclusive campaign treatment sponsor and will donate up to
three million full courses of Coartem(®) Dispersible, its pediatric
antimalarial, doubling the impact of public donations
* Novartis, a long-standing leader in malaria control and elimination, has
delivered 200 million pediatric antimalarial treatments without profit to
malaria-endemic countries since 2009
Basel, Switzerland, September 23, 2013 - Novartis and Malaria No More announced
today the debut of the Power of One (www.Po1.org) campaign, encouraging people
around the world to help end child deaths from malaria. Novartis will support
the campaign financially and donate up to three million Coartem(®) Dispersible
treatments to match antimalarials funded by the public. The company's commitment
to Power of One aligns with its long history in the fight against malaria; the
Novartis Malaria Initiative is one of the largest access-to-medicine programs in
the healthcare industry.
Malaria is a preventable and treatable disease, but it still kills a child every
minute. It is estimated that over 300 million additional treatments will be
needed to treat malaria patients across Africa between now and the end of 2015.
The Power of One campaign aims to address this treatment gap through direct
donations and existing government commitments. Every dollar donated to the
campaign will buy and deliver a treatment to a child diagnosed with malaria.
"I am proud of the significant and longstanding commitment Novartis has to the
fight against malaria. For all our progress though, there's still more work to
do" said Joseph Jimenez, CEO of Novartis. "We need more help to close the
treatment gap and Power of One offers everyone a chance to engage and make a
difference for children suffering from malaria."
Harnessing social, mobile, and e-commerce technologies, Power of One enables the
public to purchase a treatment and track the journey of a treatment. Donors will
be able to see the effect of their donation on the ground, share information
with their networks and recruit other donors.
"It's unacceptable that a child dies every minute for lack of a dollar's worth
of treatment," said Martin Edlund, CEO, Malaria No More. "We're urging the world
to join the Power of One campaign and to donate and engage their friends in this
fight."
Novartis is the exclusive treatment sponsor of the Power of One campaign,
joining some of the world's most innovative companies. Additional sponsors
include Alere Inc., which will provide malaria rapid diagnostic tests, 21st
Century Fox, AHAlife.com, Causes.com, Time Warner, Twitter, Venmo and others.
Zambia will be the first country to receive deliveries of treatments and tests
as a result of the Power of One campaign.
Novartis reaches 200 million deliveries of Coartem(®) Dispersible
Since 2009, Novartis has delivered 200 million treatments of its pediatric
antimalarial Coartem(®) Dispersible without profit to more than 50 malaria-
endemic countries. Never before have so many pediatric treatments been
distributed in such a short time frame for children suffering from malaria. The
200 millionth treatment was delivered to Zambia, which also received the first
consignment of Novartis treatments for the Power of One campaign, raised during
World Malaria Day on April 25, 2013.
"MMV applauds Novartis on this laudable achievement," said David Reddy, CEO of
Medicines for Malaria Venture. "Novartis has done a tremendous job of bringing
an innovative drug to the vulnerable young victims of malaria in Zambia and over
50 other countries, giving it global reach. We at MMV are proud to have
partnered with Novartis on the development of this important formulation."
The Novartis Malaria Initiative is one of the largest access-to-medicine
programs in the healthcare industry. Moving forward, Novartis is committed to
malaria elimination by driving the development of the next generation
antimalarials, with two new classes of anti-malaria drugs currently in
development. The most advanced compound is in Phase II clinical trials.
For more information: www.malaria.novartis.com
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines and
diagnostic tools, over-the-counter and animal health products. Novartis is the
only global company with leading positions in these areas. In 2012, the Group
achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted
to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 131,000
full-time-equivalent associates and operate in more than 140 countries around
the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
Eric Althoff Nadine Schecker
Novartis Global Media Relations Novartis Malaria Initiative Communications
+41 61 324 7999 (direct) +41 61 696 8633 (direct)
+41 79 593 4202 (mobile) +41 79 682 1326 (mobile)
eric.althoff(at)novartis.com nadine.schecker(at)novartis.com
Beth Calitri
Novartis Global Media Relations
+41 61 324 7973 (direct)
+41 79 523 0198 (mobile)
beth.calitri(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301
Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445
Isabella Zinck +41 61 324 7188
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1730582/578380.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
[HUG#1730582]
Unternehmensinformation / Kurzprofil:
Datum: 23.09.2013 - 07:21 Uhr
Sprache: Deutsch
News-ID 298928
Anzahl Zeichen: 8366
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 269 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Malaria No More and Novartis launch Power of One, a global digital fundraising campaign to help eliminate malaria deaths"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
